111 related articles for article (PubMed ID: 25518350)
1. [Gene therapy for castration resistant prostate cancer].
Nasu Y
Nihon Rinsho; 2014 Dec; 72(12):2152-7. PubMed ID: 25518350
[TBL] [Abstract][Full Text] [Related]
2. [Antisense oligodeoxynucleotide therapy for castration-resistant prostate cancer].
Miyake H; Fujisawa M
Nihon Rinsho; 2014 Dec; 72(12):2121-5. PubMed ID: 25518344
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation and diagnosis for castration resistant prostate cancer: CRPC].
Kamoto T
Nihon Rinsho; 2014 Dec; 72(12):2103-7. PubMed ID: 25518341
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial risk in castration-resistant prostate cancer: immunotherapies show promise.
Tenuta A; Klotz L; Parker JL
BJU Int; 2014 May; 113(5b):E82-9. PubMed ID: 24053150
[TBL] [Abstract][Full Text] [Related]
5. Clinical phenotypes of castration-resistant prostate cancer.
Zhang T; Armstrong AJ
Clin Adv Hematol Oncol; 2013 Nov; 11(11):707-18. PubMed ID: 24896544
[TBL] [Abstract][Full Text] [Related]
6. Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase I-II clinical trial.
Garcia JA; Elson P; Tyler A; Triozzi P; Dreicer R
Urol Oncol; 2014 Jan; 32(1):33.e11-7. PubMed ID: 23510862
[TBL] [Abstract][Full Text] [Related]
7. The Evolving Biology of Castration-Resistant Prostate Cancer: Review of Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
Geethakumari PR; Cookson MS; Kelly WK;
Oncology (Williston Park); 2016 Feb; 30(2):187-95, 199. PubMed ID: 26888794
[TBL] [Abstract][Full Text] [Related]
8. [Current status and future direction of the treatment of CRPC (castration resistant prostate cancer)].
Akaza H
Nihon Rinsho; 2014 Dec; 72(12):2108-15. PubMed ID: 25518342
[TBL] [Abstract][Full Text] [Related]
9. Preclinical biodistribution and safety study of reduced expression in immortalized cells/Dickkopf-3-encoding adenoviral vector for prostate cancer gene therapy.
Sugimoto M; Watanabe M; Kaku H; Li SA; Noguchi H; Ueki H; Sakaguchi M; Huh NH; Nasu Y; Kumon H
Oncol Rep; 2012 Nov; 28(5):1645-52. PubMed ID: 22941469
[TBL] [Abstract][Full Text] [Related]
10. The Role of Next-Generation Sequencing in Castration-Resistant Prostate Cancer Treatment.
Hovelson DH; Tomlins SA
Cancer J; 2016; 22(5):357-361. PubMed ID: 27749331
[TBL] [Abstract][Full Text] [Related]
11. MiRNA 34a: a therapeutic target for castration-resistant prostate cancer.
Chalanqui MJ; O'Doherty M; Dunne NJ; McCarthy HO
Expert Opin Ther Targets; 2016 Sep; 20(9):1075-85. PubMed ID: 26942553
[TBL] [Abstract][Full Text] [Related]
12. Diethylstilbestrol for the treatment of patients with castration-resistant prostate cancer: retrospective analysis of a single institution experience.
Grenader T; Plotkin Y; Gips M; Cherny N; Gabizon A
Oncol Rep; 2014 Jan; 31(1):428-34. PubMed ID: 24247716
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid.
Saad F; Segal S; Eastham J
Eur Urol; 2014 Jan; 65(1):146-53. PubMed ID: 22633317
[TBL] [Abstract][Full Text] [Related]
14. Ad-REIC Gene Therapy: Promising Results in a Patient with Metastatic CRPC Following Chemotherapy.
Kumon H; Sasaki K; Ariyoshi Y; Sadahira T; Ebara S; Hiraki T; Kanazawa S; Yanai H; Watanabe M; Nasu Y
Clin Med Insights Oncol; 2015; 9():31-8. PubMed ID: 25861236
[TBL] [Abstract][Full Text] [Related]
15. Molecular landscape of prostate cancer: implications for current clinical trials.
Khemlina G; Ikeda S; Kurzrock R
Cancer Treat Rev; 2015 Nov; 41(9):761-6. PubMed ID: 26210103
[TBL] [Abstract][Full Text] [Related]
16. miR-663 induces castration-resistant prostate cancer transformation and predicts clinical recurrence.
Jiao L; Deng Z; Xu C; Yu Y; Li Y; Yang C; Chen J; Liu Z; Huang G; Li LC; Sun Y
J Cell Physiol; 2014 Jul; 229(7):834-44. PubMed ID: 24243035
[TBL] [Abstract][Full Text] [Related]
17. Infectivity-Enhanced, Conditionally Replicative Adenovirus for COX-2-Expressing Castration-Resistant Prostate Cancer.
Gavrikova T; Nakamura N; Davydova J; Antonarakis ES; Yamamoto M
Viruses; 2023 Mar; 15(4):. PubMed ID: 37112881
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor co-regulatory networks in castration-resistant prostate cancer.
Sung YY; Cheung E
Endocr Relat Cancer; 2014 Feb; 21(1):R1-R11. PubMed ID: 24152433
[TBL] [Abstract][Full Text] [Related]
19. [Chemotherapy for CRPC].
Ozono S; Furuse H
Nihon Rinsho; 2014 Dec; 72(12):2170-3. PubMed ID: 25518353
[TBL] [Abstract][Full Text] [Related]
20. Adenovirus-mediated overexpression of REIC/Dkk-3 selectively induces apoptosis in human prostate cancer cells through activation of c-Jun-NH2-kinase.
Abarzua F; Sakaguchi M; Takaishi M; Nasu Y; Kurose K; Ebara S; Miyazaki M; Namba M; Kumon H; Huh NH
Cancer Res; 2005 Nov; 65(21):9617-22. PubMed ID: 16266978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
